Wegovy ramp up: what actually happens at each stage

The morning your first pen arrives

Picture it: the DPD notification comes through, you open plain packaging, and inside is a 0.25 mg pen. Not the dose you've read about in the results studies. Not the number that appears in the trial data. Just a small, unremarkable starting point.

That's deliberate. Semaglutide (the active medicine in Wegovy) slows how quickly food leaves your stomach and dials back appetite signals in the brain. Introduced at full strength from day one, those effects land hard on your digestive system before it's had any time to adjust. The 0.25 mg step asks very little of your gut while letting your body get acquainted with the medicine. Weight loss at this stage is modest, and that's fine. The Wegovy overview page explains the wider mechanism if you want more background.

Most people inject once a week, on the same day each week. Picking a day that's easy to remember (after a Monday run, or the weekend just before a new working week starts) tends to make it stick. If payday or a bank holiday lands on your usual day and throws off your rhythm, your prescriber or patient information leaflet will tell you the acceptable window for that week; don't guess.

Side effects at this stage are usually mild: some queasiness for a day or two, perhaps less interest in large portions. The nausea and vomiting page has specific practical detail if that becomes a concern.

Weeks five through twelve: the middle steps where most of the change happens

After a month at 0.25 mg, the prescriber typically moves you to 0.5 mg. A month later, 1.0 mg. Each increase is another conversation with your body rather than a sudden demand. What most people notice is that appetite suppression becomes distinctly more noticeable from 0.5 mg onward, portions that felt normal start feeling like too much, and the mental background noise of thinking about food quiets down.

The 1.0 mg dose sits roughly where Ozempic's standard diabetes maintenance dose sits, which is why some people transitioning from that medicine for diabetes management will recognise this territory. The difference is that Wegovy's programme continues upward, aiming for 1.7 mg and then 2.4 mg, doses studied specifically for weight management rather than glycaemic control, as our semaglutide page covers in more detail.

Gastrointestinal effects (nausea, loose stools, cramping) tend to peak after each dose increase and settle over one to two weeks. If cramping is a recurring issue, this page on cramps during Wegovy treatment covers what's known and what helps. A prescriber may hold you at a dose for an extra four weeks if symptoms are making daily life difficult; that's a clinically reasonable pause, not a reason to stop altogether.

It's worth having honest check-ins with yourself and with whoever is overseeing your care about how you're feeling at each step. Our guide to check-ups during treatment explains what those reviews typically cover.

Reaching 2.4 mg, and what comes after

Sixteen weeks in, most people who tolerated each step are at 2.4 mg. The STEP 1 trial, published in the New England Journal of Medicine, found that adults using semaglutide 2.4 mg alongside lifestyle changes lost around 15% of body weight on average over 68 weeks. That result comes from sustained time at the maintenance dose, not from the ramp itself.

Since January 2026, a higher maintenance option has been available: the MHRA approved a 7.2 mg dose of semaglutide under the Wegovy licence, and in April 2026 a dedicated single-dose 7.2 mg pen received approval as well. Trials at this dose reported approximately 20.7% average weight reduction over 72 weeks. It's available for adults with a BMI of 30 or above (the same starting criteria) and reached through further titration from 2.4 mg under prescriber oversight. More on the full dose range is on a dedicated page.

Where your ramp ends up depends on the clinical picture: how well you tolerate each step, your response to treatment, and what your prescriber concludes at each review. The NHS semaglutide medicines page is a reliable patient-level reference for what to expect at each stage.

For context on what the private route to treatment typically costs, our Wegovy price comparison page sets out what's usually included (and what often isn't) when providers quote a monthly figure.

What can slow, pause or change the ramp

Not everyone moves through the schedule at exactly the four-week pace. Side effects are the most common reason a prescriber keeps someone at a lower dose for longer. Significant nausea, persistent vomiting, or symptoms suggesting a gallbladder or pancreatic issue should always be discussed with a clinician rather than pushed through. The MHRA has specifically highlighted acute pancreatitis as an infrequent but serious consideration with GLP-1 medicines, severe stomach pain that radiates to the back warrants urgent medical attention, not a wait-and-see approach.

Illness during the ramp is common enough to plan for. A bad stomach bug while you're at 1.0 mg, for example, can intensify GI symptoms temporarily; in some cases a prescriber will suggest staying at that dose for an extra cycle before moving up. Pregnancy, breastfeeding, and trying to conceive are situations where Wegovy isn't recommended at any dose, a prescriber discussion is essential if your circumstances change.

Oral contraceptives also deserve a mention: there is no established evidence that semaglutide reduces pill absorption the way tirzepatide can, but this is worth discussing with your prescriber as part of any clinical review. If you have questions our team hasn't covered, the FAQs page is a reasonable starting point, and the contact page reaches our aftercare team directly.

When you're ready to understand whether this treatment is right for you, checking your eligibility takes a few minutes and is reviewed the same day by a real prescriber.